GlassScriptPhysician profile
Hamza Guend
NPI 1902110364
$4,829.48
in general payments reported to CMS, 2019-2025
15 companies · $539 in 2025
The $539 reported for 2025 was more than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,403 · 2020: $585 · 2021: $135 · 2022: $526 · 2023: $323 · 2024: $318 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,179.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,272.43 | 2019-2022 | |
| Allen Medical Systems | $800.00 | 2019 | |
| Abbott Laboratories | $720.53 | 2022-2025 | Esprit, Jeti |
| Boston Scientific Corporation | $130.49 | 2025 | Axonics |
| Abbvie INC. | $124.99 | 2023 | |
| Phathom Pharmaceuticals, INC. | $124.99 | 2024 | Voquezna |
| Coloplast Corp | $122.63 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $121.75 | 2021 | |
| Axonics, INC. | $116.40 | 2022 | |
| Covidien LP | $107.43 | 2019 | |
| Janssen Biotech, INC. | $107.37 | 2025 | Tremfya |
| Kci USA, INC. | $34.73 | 2019-2023 | V.A.C. Veraflo, Prevena, Activ.A.C. |
| Ethicon US, LLC | $20.84 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.13 | 2021 | |
| Medtronic, INC. | $11.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hamza Guend listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.